memo-inOncology – SPECIAL ISSUE

Find out the latest news from international oncology congresses and stay at the forefront of clinical innovation and advances in lung cancer research.

The memo inOncology Medical education series: keeping oncologists at the forefront of lung cancer research. memo – inOncology Special Issue Preceptorship reports summarise the latest in lung cancer research and treatments to come out of our sponsored Preceptorship meeting series. The Fundamentals of Designing Clinical Trials series arms oncologists with the information they need to plan and conduct an oncology trial.

Latest congress reports

REGISTER

Get a notification for every published memo – inOncology SPECIAL ISSUE. Register below.


    LATEST NEWS

    ESMO 2021 ST-Cover

    memo – inOncology SPECIAL ISSUE

    Congress Report virtual ESMO Solid Tumors 2021

    A GLOBAL DIGEST ON APPROACHES IN ADVANCED SOLID TUMORS
    Report from the ESMO Congress, 16th – 21st September 2021, virtual congress

    Now available!

    WCLC ESMO 2021 Cover

    memo – inOncology SPECIAL ISSUE

    Congress Report ESMO Lung Cancer 2021

    A GLOBAL CONGRESS DIGEST ON LUNG CANCER
    Report from the virtual World Conference on Lung Cancer, 8th–14th September 2021, and the virtual ESMO Congress, 16th–21st September, 2021

    Now available!

    VIEW ALL OUR REPORTS

    EXPERT VIDEOS

    All videointerviews from virtual ESMO Solid Tumors 2021

    Yelena Y. Janjigian talks about the practice-changing results obtained in the CheckMate 649 trial and how the proportion of patients with advanced gastric cancer and esophageal adenocarcinoma who receive multiple treatment lines rather than just one or two can be increased. Biomarker-targeted therapies, precision medicine approaches for advanced G/GEJ cancers, the significance of chemotherapy as well as the duration of maintenance therapy are discussed, too.

    Chiara Cremolini gives an overview of strategies that might become available in the future to enhance the efficacy of immunotherapies in the setting of microsatellite-stable metastatic colorectal cancer, how to increase the proportion of patients with metastatic colorectal cancer who receive multiple treatment lines, the optimal continuum of care in 2021 in metastatic colorectal cancer and how to predict progressive disease.

    Javier Cortés highlights the superiority of trastuzumab deruxtecan compared to trastuzumab emtansine in patients with HER2-positive metastatic breast cancer and the resulting future therapy algorithm, potential combinations in the management of patients with HER2-negative breast cancer and the clinical relevance of immunotherapy-based approaches in the treatment of triple-negative breast cancer.

    Ian Chau depicts the most interesting trial results in the field of esophageal cancer at the ESMO 2021 congress, gives an outlook on personalized approaches in the setting of esophageal squamous-cell carcinoma with regard to biomarkers for checkpoint inhibitors as well as potential further improvements of the prognosis of patients with esophageal cancer.

    Ken Kato summarizes combination regimens currently investigated in the neoadjuvant treatment of patients with esophageal cancer and outlines how immunotherapy has changed the first-line treatment standards in patients with esophageal squamous-cell carcinoma and which further developments are expected for the first-and second-line setting in the future.

    All videointerviews from virtual ESMO lung cancer 2021

    Oliver Gautschi highlights the most relevant findings presented at ESMO 2021 in terms of lung cancer, innovative treatment approaches currently tested for use in patients with unresectable malignant pleural mesothelioma, immunotherapeutic approaches in the setting of thymoma and thymic carcinoma and summarizes potential strategies for the management of RET-positive NSCLC.

    Edward B. Garon relates to anticancer vaccines, an area full of promises for lung cancer patients, their potential caveats compared to other novel treatment approaches, depicts the most interesting trial results from the phase I trial of intratumoral administration of CCL21-gene modified dendritic cells combined with intravenous pembrolizumab for advanced NSCLC and explains how antibody drug conjugates like datopotamab deruxtecan, a novel TROP2-directed ADC, fit in the therapeutic landscape in the future.

    Robin Cornelissen discusses new agents developed for the treatment of NSCLC patients with EGFR or HER2 exon 20 insertion mutations, the role of next-generation sequencing in clinical practice, rare drivers of lung cancer with potential interest in the future, targeted approaches in the management of lung cancer as well as prognostic markers for survival or clinical decision making before extended pleurectomy and decortication surgery in malignant pleural mesothelioma.

    VIEW MEDICAL EDUCATION

    A CONGRESS RESOURCE

    For Oncologists and Hematologists